company background image
CTIC logo

CTI BioPharma NasdaqCM:CTIC Stock Report

Last Price

US$9.09

Market Cap

US$1.2b

7D

-0.1%

1Y

66.2%

Updated

28 Jun, 2023

Data

Company Financials +

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CTIC Stock Overview

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States.

CTIC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

CTI BioPharma Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CTI BioPharma
Historical stock prices
Current Share PriceUS$9.09
52 Week HighUS$9.10
52 Week LowUS$4.01
Beta0.83
1 Month Change0.44%
3 Month Change112.38%
1 Year Change66.18%
3 Year Change690.43%
5 Year Change73.47%
Change since IPO-99.99%

Recent News & Updates

Recent updates

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

Aug 17

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

Aug 08

CTI BioPharma: Approval Is Great, Now There's The Follow Through

Jul 19

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

Jul 07

CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset

May 04

CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating

Apr 11

CTI BioPharma: A Speculative Buy Into The PDUFA Date

Mar 01

CTI BioPharma: Long And Troubled History, Finally Approaching Approval

Dec 24

FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA

Jun 01

CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis

May 06

CTI BioPharma: Accelerated Approval Pathway Looks Attractive

Dec 06

Shareholder Returns

CTICUS BiotechsUS Market
7D-0.1%-0.5%0.6%
1Y66.2%9.6%29.5%

Return vs Industry: CTIC exceeded the US Biotechs industry which returned 7.4% over the past year.

Return vs Market: CTIC exceeded the US Market which returned 12% over the past year.

Price Volatility

Is CTIC's price volatile compared to industry and market?
CTIC volatility
CTIC Average Weekly Movement25.3%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CTIC's share price has been volatile over the past 3 months.

Volatility Over Time: CTIC's weekly volatility has increased from 15% to 25% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1991128Adam Craighttps://www.ctibiopharma.com

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.

CTI BioPharma Corp. Fundamentals Summary

How do CTI BioPharma's earnings and revenue compare to its market cap?
CTIC fundamental statistics
Market capUS$1.20b
Earnings (TTM)-US$69.24m
Revenue (TTM)US$75.77m

15.8x

P/S Ratio

-17.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CTIC income statement (TTM)
RevenueUS$75.77m
Cost of RevenueUS$4.46m
Gross ProfitUS$71.31m
Other ExpensesUS$140.55m
Earnings-US$69.24m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.53
Gross Margin94.11%
Net Profit Margin-91.38%
Debt/Equity Ratio-459.4%

How did CTIC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.